Introduction
============

An infraclavicular block can be used to provide effective surgical anesthesia of the upper limb. However, the success rate of the infraclavicular block varies widely in the range of 40-97% \[[@B1],[@B2]\]. Various factors may affect the success rate of the infraclavicular block, such as the use of a multiple injection technique \[[@B3]\], the type of evoked motor response \[[@B4]\], the use of ultrasound guidance \[[@B5]\], and operator experience. Whether increasing the dose by volume, concentration, or a combination of the two of local anesthetics results in a higher success rate remains controversial in clinical settings.

Different combinations of volumes and concentrations of local anesthetics have been used to block the brachial plexus. In our institution, we routinely use 30 ml of local anesthetics and 0.5% ropivacaine for the infraclavicular block. In our previous study \[[@B6]\], the same volume (30 ml) of 0.75% and 0.5% ropivacaine produced similar infraclavicular block success rates and efficacy. Our hypothesis is that a further increase in the dose of local anesthetics (to the recommended maximum \[[@B7]\]) by volume (40 ml of 0.5% ropivacaine) or volume/concentration (40 ml of 0.75% ropivacaine) will yield a higher infraclavicular block success rate using neurostimulation.

The primary objective of this study was to evaluate whether increasing the dose of ropivacaine by volume or volume/concentration enhances the success rate of the vertical infraclavicular block. The secondary outcomes included block onset time, efficacy of the sensory and motor block, and adverse events.

Materials and Methods
=====================

After approval by our local ethical committee, all patients provided written informed consent. Two hundreds and ten patients (ages 18-70 years, American Society of Anesthesiologists physical status \[ASA\] I-III) scheduled for surgical procedures of the upper extremities were prospectively randomized using sealed envelopes that were opened just before the patients were included. Exclusion criteria included any contraindication to regional anesthesia, pregnancy, allergy to local anesthetics, or neurological disorders. Patients were randomly assigned to three groups: Group 1 (n = 70) received 30 ml of 0.5% ropivacaine (Naropin®, AstraZeneca, Sweden), Group 2 (n = 70) received 40 ml of 0.5% ropivacaine, and Group 3 (n = 70) received 40 ml of 0.75% ropivacaine.

For organizational and data collection purposes, blocks were performed 60 min before surgery in the recovery room. Standard monitoring was used throughout the procedure (electrocardiogram, noninvasive blood pressure, and pulse oximetry). No premedication was administered before the block. All blocks were performed by the same anesthesiologist using a nerve stimulator (Stimuplex® HNS 12, B. Braun, Germany) and a 22-gauge, 50-mm insulated needle (Stimuplex® A, B. Braun, Germany). The initial nerve stimulator settings were 1.5 mA, 0.1 ms, and 1 Hz.

The vertical infraclavicular block was performed with the patient in the supine position with their upper arm to their side and their palm facing up. After landmarks were identified, the puncture site was marked half way between the jugular notch and the ventral process of the acromion. After subcutaneous infiltration with 2 ml of 1% lidocaine, the needle was initially introduced absolutely vertical to the horizontal plane. The needle was advanced until a distal motor response of the hand or wrist was elicited. If no response was elicited upon needle insertion, the needle was reintroduced, with a slight deviation in the caudal, cranial, or lateral (not medial) direction until a motor response was obtained.

Needle position was considered adequate when a distal motor response of the median or ulnar nerve was obtained (flexion of the wrist and/or fingers) and remained visible at a current intensity of ≤ 0.5-mA. Predetermined ropivacaine was injected slowly in 5-ml increments with intermittent aspiration.

After local anesthetic administration, a blinded observer evaluated the block. Sensory block was assessed in the distribution of radial, median, ulnar, musculocutaneous, and medial antebrachial cutaneous nerve by cold testing using alcohol swabs with the following scale: 0 = normal sensation, 1 = reduced sensation to cold, and 2 = no sensation to cold. Sensory blocks were evaluated every 1 min until 50 min or a complete sensory block was achieved. Time 0 (zero) was designated the end of the local anesthetic injection. A block was defined as successful when a cold response was abolished in all five nerves distal to the elbow within 50 min after the injection of the drug. The block was considered incomplete if analgesia was not present in one or more of the nerve distributions within 50 min. The time between the end of the injection and the development of a successful block was defined as the block onset time.

Motor blocks were evaluated every 10 min until 50 min or complete motor block was achieved. The motor block was evaluated using forearm flexion, thumb abduction, thumb opposition, and thumb adduction (for the musculocutaneous, radial, median, and ulnar nerve, respectively) and scored as follows: 0 = no change, 1 = reduced power, and 2 = complete loss of power.

After the 50 min study period, the patient was taken to the operating room. If the sensory and motor blocks were complete prior to the 50 min mark, surgery commenced early. Those patients who requested sedation for the surgery was administered a continuous IV infusion of propofol at 2-3 mg/kg/h. If a patient complained of pain at the surgical site, the block was supplemented by the continuous infusion of propofol at 2-4 mg/kg/h and sufentanil 0.1-0.3 µg/kg IV. If this measure did not provide adequate pain control, then general anesthesia was induced.

Surgical procedures, surgery time, tourniquet time, and tourniquet pain were recorded. Adverse events, such as vascular puncture, local anesthetic toxicity, Horner\'s syndrome, dyspnea, and pneumothorax were also noted.

The success rate at 50 min was chosen as the primary endpoint. Assumptions for the sample-size analysis were based on the success rate of our previous study \[[@B8]\], in which a vertical infraclavicular block yielded a success rate of 82%. A cohort of 66 subjects would have 80% power to detect a clinically important (15%) difference in success rate among the groups upon acceptance of an α error of 5% and a β error of 20%. Four extra patients were included to allow for possible dropouts.

Statistical analyses were performed using SPSS 12.0 KO (SPSS Inc., Chicago, US). Continuous variables were presented as mean (SD) or median (range) according to the data distribution. Quantitative variables in the three study groups were compared using one-way analysis of variance (ANOVA) with Bonferroni\'s correction in the post-hoc analyses. The Kruskal-Wallis test was used as a non-parametric alternative. Categorical variables were presented as number of patients (%). Comparison of categorical variables was carried out using the χ^2^ test (Fisher\'s exact test, if necessary). A value of P \< 0.05 was considered statistically significant.

Results
=======

A total of 210 patients were recruited. It was not possible to elicit a typical median or ulnar nerve response in one patient in Group 1, so this patient was excluded from the study. No difference was found among groups in regard to demographic and surgical data ([Table 1](#T1){ref-type="table"}). [Table 2](#T2){ref-type="table"} shows the block success and failure rates. The overall success rate was 94.7%. The success rate did not differ significantly among groups, although it was higher in Groups 2 and 3 than Group 1 (P = 0.346). Blocks sufficient for surgery and supplementation were comparable among groups. One patient in Group 1 needed general anesthesia due to complete block failure. Three patients in Group 1 and two patients in Group 2 reported tourniquet pain (not statistically significant). Intraoperative sedation was requested by 14, 8, and 15 patients for Group 1, 2, and 3, respectively (not statistically significant).

Block onset time was 9 (2-45), 8 (2-48), and 6 (2-46) min for Groups 1, 2, and 3, respectively. Although onset time tended to be shorter in Group 3, there was no significant difference among groups (P = 0.225). [Fig. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} show the percentage of successful sensory blocks by nerve and the percentage of patients in whom a complete sensory block was achieved over time, respectively. There were no statistically significant differences among groups in these outcomes.

[Fig. 3](#F3){ref-type="fig"} shows the percentage of complete motor block achieved by nerve within 50-min study period. Significant differences among groups were found in the median (at 10, 20, 30, and 40 min), ulnar (at 20, 30, 40, and 50 min), and musculocutaneous (at 10 and 20 min) nerves among groups (P \< 0.05). [Fig. 4](#F4){ref-type="fig"} shows the percentage of patients in whom a complete motor block was achieved over time. There were significant differences among groups in the percentage of achieved complete motor blocks over time (P \< 0.05).

[Table 3](#T3){ref-type="table"} shows the adverse events observed in this study. No differences were found in vascular puncture, Horner\'s syndrome, and dyspnea among groups. Signs and symptoms of local anesthetic toxicity were observed in five patients in Group 3 (P = 0.006). Of those, one patient developed generalized tonic - clonic seizure activity. All six patients were administered propofol and recovered without any complications.

Discussion
==========

In this randomized study, we show that increasing the dose of ropivacaine by volume or volume/concentration does not necessarily lead to any clinically significant advantages with regard to vertical infraclavicular block. Importantly, increasing the doses of ropivacaine (300 mg) can induce systemic toxicity of the local anesthetic in female patients.

The success rates of our previous studies were 70-88% \[[@B6],[@B8],[@B9]\]. In this study, we hypothesize that increasing the dose of local anesthetics will enhance the infraclavicular block success rate and efficacy. Therefore, we increased the dose of local anesthetics by increasing only volume (two variables) and then by increasing the concentration as well (three variables). The success rate was higher in Groups 2 (97.1%) and 3 (94.2%) than in Group 1 (92.8%), although there were no significant differences among groups. Tran de et al. \[[@B10]\] recently reported a minimum effective volume of 35 ml for ultrasound-guided infraclavicular block in 90% of patients. Compared with neurostimulation, ultrasound can reduce local anesthetic requirements. Therefore, it is our recommendation that use of 40 ml of 0.5% ropivacaine is more suitable for vertical infraclavicular blocks using neurostimulation considering the block efficacy and toxicity of local anesthetics.

The effects of increasing the dose of local anesthetics on success rate or efficacy of the brachial plexus block remain controversial. Vester-Andersen et al. \[[@B11]\] reported that when concentration was held constant, increasing doses by volume resulted in no difference in sensory or motor anesthesia. When volume was held constant, sensory blocks were 70-100% successful in all nerve groups regardless of concentration increases \[[@B12]\]. In contrast, Casati et al. \[[@B13]\] reported that increasing the dose of local anesthetics by increasing the concentration without changing the injected volume shortened sensory and motor onset times but did not increase the block success rate.

In this study, why increasing the dose of local anesthetics by volume or volume/concentration does not lead to a higher success rate remains unclear. It may be caused by the fact that a relatively high dose of local anesthetic is already injected. If corrected for weights, then perhaps a difference in success rate would have been detected. Another reason is that the septa around the cords can prevent effective spread of local anesthetic. Morimoto et al. \[[@B14]\] reported that the presence of septae within the neurovascular sheath influenced the pattern of local anesthetic spread.

In this study, increasing dose enhanced motor block efficacy. Compared with Group 1, increasing dose, especially Group 3, produced a higher percentage of patients with complete motor block for each nerve (except the radial) and all nerves over time. These results were consistent with those of the previous study \[[@B13]\], which may be due to the fact that more local anesthetic molecules in Groups 2 and 3 in the current study were available to penetrate the peripheral nerves per unit time.

There is considerable variability in the arterial plasma concentrations of ropivacaine after injection for a vertical infraclavicular block, but peak plasma concentrations occur at 20-30 min \[[@B15]\]. In this study, neurologic toxicity occurred in all female patients 16-30 min after block induction, indicating rapid absorption of a relatively large dose of ropivacaine (5-6.38 mg/kg).

We are not aware of any reason why females should be susceptible to local ropivacaine toxicity, but there are two possible explanations: the pharmacokinetic difference between men and women, or that 300 mg of ropivacaine may have been excessive in some patients. Several previous reports \[[@B16]-[@B19]\] have stated that 300 mg of local ropivacaine could produce systemic toxicity. It is difficult to recommend a safe maximum dose of ropivacaine, but doses of local anesthetics should be block-specific, site-specific, and patient-specific \[[@B7]\].

Epinephrine is often added to local anesthetic agents to reduce systemic absorption by causing local vasoconstriction and potentially limit systemic local anesthetic toxicity by reducing time-to-peak concentrations and peak plasma concentrations. However, Hickey et al. \[[@B20]\] reported that the addition of epinephrine did not alter the pharmacokinetic properties of ropivacaine when used for subclavian perivascular brachial plexus blocks. Therefore, we did not add epinephrine to ropivacaine in this study.

This study had some limitations. First, we performed infraclavicular blocks using neurostimulation. This possibly reflects a deficit in placement of local anesthetic, i.e., how much of the injectate in each case was actually delivered around the cords. Without the use of ultrasound, we cannot know whether the local anesthetic was placed accurately, a deficit of many older studies examining dose response for peripheral nerve blocks. Second, a single anesthesiologist performed all of the blocks. Although this eliminates inter-operator variability, it might limit the generalizability of the results. Third, the type of evoked distal response is an important factor that influences overall infraclavicular block success. In this study, we decided to accept only evoked responses of the median or ulnar nerves in the hand or wrist as valid to avoid confounding factors. Our own experience and that of others \[[@B21]\] have shown that a median or ulnar nerve response yields a higher success rate than a radial nerve response. However, these findings need to be confirmed by a randomized study to further influence the type of evoked distal motor responses on success rate during vertical infraclavicular blocks.

In conclusion, the results of this prospective, randomized, double-blind study demonstrate that increasing the doses of ropivacaine by volume or volume/concentration does not improve sensory block success rate, onset time, or efficacy; rather it improved motor block efficacy only during vertical infraclavicular blocks. It is our recommendation that the use of 40 ml of 0.5% ropivacaine may be more appropriate for vertical infraclavicular blocks considering block efficacy and the toxicity of local anesthetics.
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###### 

Demographic and Surgical Data

![](kjae-63-36-i001)

Values are mean ± SD or number of patients. ASA: American Society of Anesthesiologists. Group 1: infraclavicular block with 30 ml of 0.5% ropivacaine. Group 2: infraclavicular block with 40 ml of 0.5% ropivacaine. Group 3: infraclavicular block with 40 ml of 0.75% ropivacaine.

###### 

Block Success and Failure Rates
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The values are the number of patients (%). Group 1: infraclavicular block with 30 ml of 0.5% ropivacaine. Group 2: infraclavicular block with 40 ml of 0.5% ropivacaine. Group 3: infraclavicular block with 40 ml of 0.75% ropivacaine.

###### 

Adverse Events
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The values are the number of patients (%). LA: local anesthetic. Group 1: infraclavicular block with 30 ml of 0.5% ropivacaine. Group 2: infraclavicular block with 40 ml of 0.5% ropivacaine. Group 3: infraclavicular block with 40 ml of 0.75% ropivacaine. ^\*^P \< 0.05 among groups.
